Tra My Pham , Angela M. Crook , Katie Rolfe , Patrick P.J. Phillips , Suzanne M. Dufault , Matteo Quartagno , on behalf of UNITE4TB Work Package 2
{"title":"设计一项反应过度连续干预(ROCI)随机试验:在paradigm m4tb试验的2C期部分(持续时间范围)实施。","authors":"Tra My Pham , Angela M. Crook , Katie Rolfe , Patrick P.J. Phillips , Suzanne M. Dufault , Matteo Quartagno , on behalf of UNITE4TB Work Package 2","doi":"10.1016/j.cct.2025.108002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Aims</h3><div>Treatments for tuberculosis (TB) are often long and complicated. Standard 2-arm non-inferiority trials have been used to evaluate shorter durations of treatment regimens. The new response-over-continuous-intervention (ROCI) trial design has recently been proposed as a practical alternative for optimising some continuous aspect (e.g. treatment duration) of treatment administration.</div></div><div><h3>Methods</h3><div>We demonstrate the use of simulation for designing a ROCI trial in the TB setting. We use the Phase 2C part (duration ranging) of the PARADIGM4TB trial as a case study to illustrate the simulation procedure and the important design considerations to be explored in simulation. Phase 2C of PARADIGM4TB aims to optimise durations of novel treatment regimens, compared to a 6-month standard-of-care treatment regimen, with the aim to support advancement to Phase 3 trials.</div></div><div><h3>Results</h3><div>A ROCI design randomising 200 patients to 5 equally spaced duration arms of the novel treatment regimen (with an additional 40 patients randomised to the standard-of-care treatment regimen) is sufficient to achieve reasonable power to identify the optimal duration in a range of scenarios. Modelling the duration-response curve with a fractional polynomial model of degree 1 improves power to select shorter durations compared with pairwise comparisons. A design with 5 durations of the novel regimen is preferred to a design with 3 durations, because of the improved operating characteristics in scenarios where the duration-response curve is not flat.</div></div><div><h3>Conclusions</h3><div>The ROCI design is an appealing design option for TB treatment trials. The design of ROCI trials can be done by conducting simulation studies to explore key design considerations.</div></div>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":"155 ","pages":"Article 108002"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Designing a response-over-continuous-intervention (ROCI) randomised trial: Implementation in the Phase 2C part (duration ranging) of the PARADIGM4TB trial\",\"authors\":\"Tra My Pham , Angela M. Crook , Katie Rolfe , Patrick P.J. Phillips , Suzanne M. Dufault , Matteo Quartagno , on behalf of UNITE4TB Work Package 2\",\"doi\":\"10.1016/j.cct.2025.108002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background/Aims</h3><div>Treatments for tuberculosis (TB) are often long and complicated. Standard 2-arm non-inferiority trials have been used to evaluate shorter durations of treatment regimens. The new response-over-continuous-intervention (ROCI) trial design has recently been proposed as a practical alternative for optimising some continuous aspect (e.g. treatment duration) of treatment administration.</div></div><div><h3>Methods</h3><div>We demonstrate the use of simulation for designing a ROCI trial in the TB setting. We use the Phase 2C part (duration ranging) of the PARADIGM4TB trial as a case study to illustrate the simulation procedure and the important design considerations to be explored in simulation. Phase 2C of PARADIGM4TB aims to optimise durations of novel treatment regimens, compared to a 6-month standard-of-care treatment regimen, with the aim to support advancement to Phase 3 trials.</div></div><div><h3>Results</h3><div>A ROCI design randomising 200 patients to 5 equally spaced duration arms of the novel treatment regimen (with an additional 40 patients randomised to the standard-of-care treatment regimen) is sufficient to achieve reasonable power to identify the optimal duration in a range of scenarios. Modelling the duration-response curve with a fractional polynomial model of degree 1 improves power to select shorter durations compared with pairwise comparisons. A design with 5 durations of the novel regimen is preferred to a design with 3 durations, because of the improved operating characteristics in scenarios where the duration-response curve is not flat.</div></div><div><h3>Conclusions</h3><div>The ROCI design is an appealing design option for TB treatment trials. The design of ROCI trials can be done by conducting simulation studies to explore key design considerations.</div></div>\",\"PeriodicalId\":10636,\"journal\":{\"name\":\"Contemporary clinical trials\",\"volume\":\"155 \",\"pages\":\"Article 108002\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Contemporary clinical trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S155171442500196X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S155171442500196X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Designing a response-over-continuous-intervention (ROCI) randomised trial: Implementation in the Phase 2C part (duration ranging) of the PARADIGM4TB trial
Background/Aims
Treatments for tuberculosis (TB) are often long and complicated. Standard 2-arm non-inferiority trials have been used to evaluate shorter durations of treatment regimens. The new response-over-continuous-intervention (ROCI) trial design has recently been proposed as a practical alternative for optimising some continuous aspect (e.g. treatment duration) of treatment administration.
Methods
We demonstrate the use of simulation for designing a ROCI trial in the TB setting. We use the Phase 2C part (duration ranging) of the PARADIGM4TB trial as a case study to illustrate the simulation procedure and the important design considerations to be explored in simulation. Phase 2C of PARADIGM4TB aims to optimise durations of novel treatment regimens, compared to a 6-month standard-of-care treatment regimen, with the aim to support advancement to Phase 3 trials.
Results
A ROCI design randomising 200 patients to 5 equally spaced duration arms of the novel treatment regimen (with an additional 40 patients randomised to the standard-of-care treatment regimen) is sufficient to achieve reasonable power to identify the optimal duration in a range of scenarios. Modelling the duration-response curve with a fractional polynomial model of degree 1 improves power to select shorter durations compared with pairwise comparisons. A design with 5 durations of the novel regimen is preferred to a design with 3 durations, because of the improved operating characteristics in scenarios where the duration-response curve is not flat.
Conclusions
The ROCI design is an appealing design option for TB treatment trials. The design of ROCI trials can be done by conducting simulation studies to explore key design considerations.
期刊介绍:
Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.